148849-67-6 Usage
Description
In an effort to develop angina agents without the unwanted negative
inotropic and hypotensive effects associated with b-adrenergic blockers and
calcium channel blockers, a new class of heart-rate reducing compounds that act
specifically on the sinoatrial (SA) node has been explored. These bradycardic
agents interact directly with the pacemaking cell of the SA node and the hyperpolarization-
activated If , the primary pacemaking current. Ivabradine has
evolved as a specific inhibitor of If current through its contact with f-channels on
the intracellular side of the plasma membrane. As a consequence, ivabradine
reduces the speed of diastolic depolarization and decreases heart rate. It has been
approved for the treatment of chronic stable angina and provides a viable
alternative to patients with a contraindication or intolerance of b-blockers. Evaluation
is also underway for the potential treatment of ischemic heart disease.
Using a patch-clamp technique on rabbit sinoatrial node cells, inhibition of If
current ranged from 6% (0.03 mM) – 80% (10 mM).
.
Chemical Properties
White to Off-White Solid
Originator
Servier (France)
Uses
Different sources of media describe the Uses of 148849-67-6 differently. You can refer to the following data:
1. Ivabradine hydrochloride has been used as a potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel (HCN)2 blocker in embryoid body (EB) and rat engineered heart tissue (EHT).
2. Ivabradine HCl, a new If inhibitor with IC 50 of 2.9 μM which acts specifically on the pacemaker activity of the sinoatrial node, is a pure heart rate lowering agent
3. angina therapeutic
4. Selective bradycardic agent with direct effect on the pacemaker If current of the sinoatrial node. Antianginal
Definition
ChEBI: A hydrochloride obtained by combining ivabradine with one molar equivalent of hydrochloric acid. Used to treat patients with angina who have intolerance to beta blockers and/or heart failure.
Brand name
Procoralan
Biochem/physiol Actions
Ivabradine is used to treat chronic heart failure.
Clinical Use
Symptomatic treatment of chronic stable angina pectoris
in patients with sinus rhythm
Treatment of mild to severe chronic heart failure
Drug interactions
Potentially hazardous interactions with other drugs
Anti-arrhythmics: increased risk of ventricular
arrhythmias with amiodarone and disopyramide.
Antibacterials: concentration possibly increased by
clarithromycin and telithromycin - avoid; increased
risk of ventricular arrhythmias with erythromycin -
avoid.
Antifungals: concentration increased by ketoconazole
- avoid; concentration increased by fluconazole -
reduce initial ivabradine dose; concentration possibly
increased by itraconazole - avoid.
Antimalarials: increased risk of ventricular
arrhythmias with mefloquine.
Antipsychotics: increased risk of ventricular
arrhythmias with pimozide.
Antivirals: concentration possibly increased by
ritonavir - avoid.
Beta-blockers: increased risk of ventricular
arrhythmias with sotalol.
Calcium-channel blockers: concentration increased
by diltiazem and verapamil - avoid.
Grapefruit juice: ivabradine concentration increased.
Pentamidine: increased risk of ventricular
arrhythmias.
St John’s wort: ivabradine concentration reduced -
avoid.
Metabolism
Ivabradine is extensively metabolised by the liver
and the gut by oxidation through cytochrome P450
3A4 (CYP3A4) only. The major active metabolite is
N-desmethyl-ivabradine (S 18982) with an exposure
about 40% of that of the parent compound. This active
metabolite undergoes further metabolism by CYP3A4.
Excretion of metabolites occurs to a similar extent via
faeces and urine.
Check Digit Verification of cas no
The CAS Registry Mumber 148849-67-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,8,8,4 and 9 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 148849-67:
(8*1)+(7*4)+(6*8)+(5*8)+(4*4)+(3*9)+(2*6)+(1*7)=186
186 % 10 = 6
So 148849-67-6 is a valid CAS Registry Number.
InChI:InChI=1/C27H36N2O5.ClH/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;/h12-14,16,21H,6-11,15,17H2,1-5H3;1H/t21-;/m1./s1
148849-67-6Relevant articles and documents
Preparation method of high-purity ivabradine hydrochloride and intermediate thereof
-
Paragraph 0056-0062, (2019/12/02)
The invention discloses a preparation method of high-purity ivabradine hydrochloride and an intermediate thereof. According to the invention, a specific refining method is adopted; by-products generated in the preparation process are effectively removed, wherein the byproducts refer to an impurity shown in a formula I and an impurity shown in a formula II. Results confirm that the purity of the ivabradine intermediate shown in the formula IV is remarkably improved, and the contents of the impurity compound shown in the formula I and the impurity shown in the formula II in the ivabradine intermediate shown in the formula IV are controlled within the range of less than 0.1%, so that the purity of the subsequently prepared ivabradine hydrochloride can be improved. And in the process of preparing ivabradine hydrochloride by using the prepared ivabradine intermediate shown in the formula IV, impurities shown in the formula II are further removed by re-utilizing a recrystallization mode of amixed solution of acetyl chloride, acetone and ethanol. The impurity shown in the formula I and the impurity shown in the formula II obtained by separation can be used as impurity reference substances for quality control of an ivabradine raw material and a preparation thereof.
(1 S) - 4, 5 - dimethoxy - 1 - [(methylamino) methyl] benzocyclobutane preparation of hydrochloride salts of method
-
Paragraph 0137; 0138; 0139, (2018/04/02)
The invention provides a preparation method of (1S)-4,5-dimethoxy-1-[(methylamino)methyl]benzocyclobutane hydrochloride, which specially comprises the following step: carrying out reduction and salting-out on 4,5-dimethoxybenzocyclobutyl-1-methyl formamide in an inert solvent to finally obtain the (1S)-4,5-dimethoxy-1-[(methylamino)methyl]benzocyclobutane hydrochloride (I). The reaction is simple to operate, has the advantages of mild reaction conditions, clean and accessible raw/auxiliary materials, low overall cost, high chemical and enantiomer purity and the like, and therefore, is suitable for industrial production.
Exploiting the Biocatalytic Toolbox for the Asymmetric Synthesis of the Heart-Rate Reducing Agent Ivabradine
Pedragosa-Moreau, Sandrine,Le Flohic, Alexandre,Thienpondt, Vivien,Lefoulon, Fran?ois,Petit, Anne-Marie,Ríos-Lombardía, Nicolás,Morís, Francisco,González-Sabín, Javier
supporting information, p. 485 - 493 (2017/02/10)
Several chemoenzymatic routes have been evaluated for the production of the heart-rate reducing agent ivabradine. Lipases and ω-transaminases have been identified as useful biocatalysts for the preparation of key enantiopure precursors. The lipase-catalysed kinetic resolution by alkoxycarbonylation of a racemic primary amine and subsequent chemical reduction of the resulting carbamate provided an N-methylated (S)-amine, one step away from ivabradine. Alternatively, the dynamic kinetic resolution by asymmetric bioamination of an aldehyde precursor enabled, in a four-step sequence, the preparative scale synthesis of enantiopure ivabradine in 50% overall yield. (Figure presented.).